HRs by outcome in different follow-up time frames after SVT
| . | Adjusted HR (95% CI)* . | ||||
|---|---|---|---|---|---|
| Outcome . | Overall . | 0-3 mo . | >3 mo-1 y . | >1 y-5 y . | >5 y . |
| VTE | 8.55 (8.07-9.05) | 71.40 (60.16-84.74) | 16.21 (13.92-18.87) | 7.32 (6.59-8.12) | 5.05 (4.61-5.54) |
| Unprovoked VTE | 9.98 (9.33-10.68) | 69.91 (56.56-86.41) | 17.59 (14.60-21.20) | 9.01 (7.98-10.16) | 6.32 (5.69-7.02) |
| Provoked VTE | 6.13 (5.51-6.82) | 59.21 (43.75-80.12) | 13.56 (10.33-17.78) | 4.55 (3.69-5.62) | 3.10 (2.57-3.74) |
| DVT | 11.28 (10.53-12.08) | 87.69 (70.84-108.55) | 23.84 (19.88-28.60) | 10.07 (8.89-11.41) | 6.26 (5.60-7.00) |
| PE | 4.53 (4.09-5.03) | 45.44 (33.91-60.89) | 7.23 (5.36-9.75) | 3.85 (3.18-4.66) | 2.94 (2.50-3.46) |
| AMI | 1.17 (1.08-1.28) | 1.62 (1.04-2.51) | 1.60 (1.23-2.09) | 1.08 (0.93-1.25) | 1.15 (1.02-1.29) |
| Ischemic stroke | 1.28 (1.18-1.38) | 2.62 (1.82-3.78) | 1.45 (1.09-1.94) | 1.17 (1.01-1.35) | 1.26 (1.14-1.39) |
| Death | 1.27 (1.23-1.31) | 3.50 (3.09-3.96) | 2.15 (1.96-2.36) | 1.12 (1.06-1.19) | 1.16 (1.11-1.21) |
| . | Adjusted HR (95% CI)* . | ||||
|---|---|---|---|---|---|
| Outcome . | Overall . | 0-3 mo . | >3 mo-1 y . | >1 y-5 y . | >5 y . |
| VTE | 8.55 (8.07-9.05) | 71.40 (60.16-84.74) | 16.21 (13.92-18.87) | 7.32 (6.59-8.12) | 5.05 (4.61-5.54) |
| Unprovoked VTE | 9.98 (9.33-10.68) | 69.91 (56.56-86.41) | 17.59 (14.60-21.20) | 9.01 (7.98-10.16) | 6.32 (5.69-7.02) |
| Provoked VTE | 6.13 (5.51-6.82) | 59.21 (43.75-80.12) | 13.56 (10.33-17.78) | 4.55 (3.69-5.62) | 3.10 (2.57-3.74) |
| DVT | 11.28 (10.53-12.08) | 87.69 (70.84-108.55) | 23.84 (19.88-28.60) | 10.07 (8.89-11.41) | 6.26 (5.60-7.00) |
| PE | 4.53 (4.09-5.03) | 45.44 (33.91-60.89) | 7.23 (5.36-9.75) | 3.85 (3.18-4.66) | 2.94 (2.50-3.46) |
| AMI | 1.17 (1.08-1.28) | 1.62 (1.04-2.51) | 1.60 (1.23-2.09) | 1.08 (0.93-1.25) | 1.15 (1.02-1.29) |
| Ischemic stroke | 1.28 (1.18-1.38) | 2.62 (1.82-3.78) | 1.45 (1.09-1.94) | 1.17 (1.01-1.35) | 1.26 (1.14-1.39) |
| Death | 1.27 (1.23-1.31) | 3.50 (3.09-3.96) | 2.15 (1.96-2.36) | 1.12 (1.06-1.19) | 1.16 (1.11-1.21) |
Adjusted for cancer, pregnancy, fracture, surgery, CCI score, and autoimmune disease. All hazard ratios compare the SVT cohort with the population cohort as the reference group.